Objective-Senescent pulmonary artery smooth muscle cells (PA-SMCs) may contribute to the pathogenesis of pulmonary hypertension by producing secreted factors. The aim of this study was to explore the role in pulmonary hypertension of extracellular matrix proteins released by senescent PA-SMCs. Approach and Results-Polymerase chain reaction array analysis of human PA-SMCs undergoing replicative senescence revealed osteopontin upregulation, which mediated the stimulatory effect of senescent PA-SMC media and matrix on PA-SMC growth and migration. Osteopontin was upregulated in lungs from patients with chronic obstructive pulmonary disease or idiopathic pulmonary arterial hypertension. Prominent osteopontin immunostaining was noted in PASMCs that also stained for p16 at sites of vascular hypertrophy, and lung osteopontin levels correlated closely with age. Compared with younger mice, 1-year-old mice displayed higher lung osteopontin levels, right ventricular systolic pressure, pulmonary vessel muscularization, and numbers of PA-SMCs stained for p16 or p21 and also for osteopontin.
C ell senescence, defined as a stable cell-cycle arrest combined with stereotyped cellular changes, is now recognized as a key biological process associated with age-related pathologies including those targeting the lung. 1 The high level of metabolic activity of senescent cells and their secretion of numerous factors is known as the senescence-associated secretory phenotype (SASP). 2 Senescent cells, through the SASP, may signal the presence of damaged cells requiring elimination by the immune system. However, when senescent cells cannot be eliminated, the SASP may produce remodeling factors, thus altering the microenvironment and contributing to tissue remodeling. 3, 4 The role for senescent cells in the pathogenesis of pulmonary vascular remodeling and pulmonary hypertension (PH) remains unclear. 4, 5 In PH, both beneficial and detrimental effects of cell senescence have been reported. PH is primarily a proliferative disease resulting from hyperplasia of pulmonary vascular cells, and inducing cell senescence may be capable of halting the abnormal proliferative process. In animal models of PH, we showed recently that inducing cell senescence prevented and reversed PH. 6, 7 These findings are consistent with the well-established concept that cellular senescence safeguards against uncontrolled cell proliferation. 3 Thus, inducing cell senescence may be beneficial in PH, provided the senescent cells are cleared and cannot accumulate. Accumulation of senescent cells may, however, occur in pulmonary vessels, especially during aging or in chronic lung diseases such as chronic obstructive pulmonary disease (COPD). 8, 9 In previous studies, we showed that senescent pulmonary artery smooth muscle cells (PA-SMCs) stimulated the growth and migration of normal target PA-SMCs through the secretion of paracrine-soluble and paracrineinsoluble factors, including extracellular matrix (ECM) components. 8 An unresolved issue is whether such a mechanism occurs during aging and contributes to various types of PH, including group 3 PH (PH associated with hypoxia or chronic lung disease) and group 1 PH (pulmonary arterial hypertension), which is now increasingly diagnosed in older individuals. 10 Elucidation of the mechanisms by which cell senescence may affect PH development and progression is therefore of major clinical importance. In particular, the panoply of factors secreted by senescent cells remains to be fully identified.
In this study, we explored the molecular mechanisms by which senescent PA-SMCs may contribute to pulmonary vascular remodeling and PH progression via paracrine effects on neighboring PA-SMCs. On the basis of previous evidence that ECM components are involved in this process, 8 we focused on ECM proteins released by senescent PA-SMCs and, in particular, on osteopontin (OPN). We examined the relevance of these findings in pulmonary vessels and lungs from patients with COPD and patients with idiopathic pulmonary arterial hypertension (iPAH). In addition, using cell and transgenic animal studies, we explored the role played by OPN in experimental PH according to age.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Analysis of ECM Proteins Expressed by PA-SMCs Undergoing Replicative Senescence
Given our previous finding that ECM components are secreted by senescent cells, 8 we used polymerase chain reaction array analysis to look for overexpressed ECM genes in PA-SMCs undergoing replicative senescence. We found that 13 genes were upregulated in senescent cells compared with nonsenescent cells, including the genes for OPN, tenascin C, transforming growth factor-β, and various integrins ( Figure 1A ; Figure IB in the online-only Data Supplement). Using quantitative RT-PCR (real-time polymerase chain reaction), we verified the pattern of OPN and tenascin C upregulation identified by polymerase chain reaction array analysis, as well as the absence of differences in the expression of fibronectin, collagen 4, and laminin ( Figure 1B ). For the subsequent analyses, we focused on OPN and investigated OPN expression in PA-SMCs from 11 patients with COPD and 12 controls ( Figure 1D through 1F) . We found that the percentage of β-galactosidase -positive cells was higher in patients with COPD than in controls at passage 2 and then increased with subsequent passages ( Figure 1C ). Parallel changes were observed in OPN proteins, with higher levels in cells from patients with COPD than in those from controls at any passage ( Figure 1D ). Thus, a close positive correlation was found between OPN levels and β-galactosidase-positive cell counts ( Figure 1E ). Moreover, in contrast to those from controls, PA-SMCs from patients with COPD showed marked OPN staining activity at passage 2 ( Figure 1F ). A close relationship was also found between OPN and p16 staining in senescent cells ( Figure II in the online-only Data Supplement).
Senescent PA-SMC-Derived OPN Stimulates Growth and Migration of Target PA-SMCs
As shown in Figure 2A and 2B, PA-SMC media from senescent and nonsenescent cells stimulated growth and migration of target PA-SMCs, and this effect was more marked with media from senescent versus nonsenescent cells. Neutralizing antibodies to OPN abrogated the growth-stimulating effect and partly inhibited the migratory effect, thereby eliminating the difference between senescent and nonsenescent PA-SMC culture media ( Figure 2B and 2C) .
To examine the effects of OPN as an insoluble factor, we allowed senescent or nonsenescent PA-SMCs to deposit ECM onto culture dishes. We then removed the cells without altering the matrix and introduced new healthy PA-SMCs, whose growth or migration were assessed. As shown in Figure 2E , migration of target PA-SMCs was greater in dishes coated with matrix secreted by senescent cells compared with nonsenescent cells and was completely suppressed by neutralizing antibodies to OPN. Neutralizing antibodies to OPN also reduced PA-SMC proliferation, and this effect was greater in dishes coated with matrix secreted by senescent cells compared with nonsenescent cells ( Figure 2D ). Exogenous OPN stimulates PA-SMC growth in a concentration close to that measured in PA-SMC medium from patients with COPD and controls (2.07±0.79 versus 0.48±0.14 ng/mL, respectively; P<0.05; Figures IIIA and IV in the online-only Data Supplement). This effect was mainly because of binding to an integrin RGD (Arg-Gly-Asp) sequence because it was fully inhibited by the integrin-blocking sextapeptide GRGDTP (Gly-Arg-Gly-Asp-Thr-Pro; Figure IVC in the online-only Data Supplement). To investigate whether the effects of osteopontin resulted from inhibition of cellular apoptosis, we examined the response of nonsenescent and senescent cells to exogenous OPN. As shown in Figure V in 
OPN in Lungs and Pulmonary Vessels From Patients With COPD or iPAH
We then investigated lung tissues from patients with COPD or iPAH, as well as from controls of various ages (Tables I  and II in the online-only Data Supplement). OPN levels in lung tissue were higher in patients with COPD or iPAH than in controls and correlated positively with age in patients with iPAH or COPD ( Figure 3A ). OPN expression in patients with COPD localized chiefly in the media of pulmonary vessels. Of note, PA-SMCs also positive for p16 exhibited the highest level of OPN staining, whereas no OPN staining was visible in nondividing PA-SMCs expressing α-smooth muscle actin ( Figure 3B ). In lungs from patients with iPAH, prominent immunostaining for OPN protein was found in PA-SMCs exhibiting a synthetic phenotype without expression of α-smooth muscle actin and in a few p16-positive cells located in the intima of the vessels. In patients with COPD and controls, lung OPN levels correlated positively with the wall thickness/area ratio (P<0.001).
Age-Related Changes in Lung OPN Levels and Pulmonary Vascular Remodeling in Mice
Lung OPN protein levels were low in young wild-type (WT) mice and increased with age simultaneously with lung p16 (Table III in the online-only Data Supplement). Also, the hematocrit was not different between aged WT and OPN −/− mice (43.8±0.6% versus 43.5±0.5%, respectively; P value not significant). After 21 days of hypoxia, increases were found in lung levels of OPN, p21, and p16 proteins and in percentages of p21-and p16-positive cells, in both young and older WT mice ( Figure 4C , 4E, and 4F). Compared with young WT hypoxic mice, older WT hypoxic mice also had higher lung OPN, p21, and p16 protein levels; higher percentages of p21-and p16-positive pulmonary vascular cells; and Figure 4B) . Furthermore, the distal pulmonary vessels were less muscular in OPN −/− than in WT mice, with 
Hyperplasia of Cultured PA-SMCs From Old Mice: Relation With OPN Expression
Soluble OPN levels were higher in conditioned media from 1-year-old than from 2-month-old mice, in accordance with the higher number of β-galactosidase-positive cells ( Figure 6A and 6B). PA-SMCs from 1-year-old mice grew faster than did those from young mice but not in the presence of anti-OPN antibodies ( Figure 6C ). The growth of PA-SMCs from 2-month-old or 1-year-old mice was potentiated by culture media of cells from young WT mice and, to a greater extent, from older WT mice ( Figure 6C ). In the presence of anti-OPN antibodies, these stimulatory effects were suppressed and growth of cells from young and old mice was no longer different. No growth stimulation was observed with conditioned media from OPN −/− mice ( Figure 6C ). Exogenous OPN induced PA-SMCs proliferation at concentrations similar to We then assessed the effects of nonsoluble matrix components on PA-SMC proliferation ( Figure 6D ). The growth of PA-SMCs from young WT mice was enhanced in dishes coated with matrix deposited by PA-SMCs from older mice, and this effect was suppressed by anti-OPN antibodies. was greater with PA-SMC media from older than from young WT mice ( Figure 6C) . Furthermore, the growth of PA-SMCs from OPN −/− mice was enhanced by matrix secreted by WT mice, and this effect was greater with matrix from old than from young WT mice ( Figure 6D ).
Discussion
Our results identify OPN as a critical mediator of pulmonary vascular remodeling associated with PA-SMC senescence and aging. We found that OPN was upregulated in senescent human PA-SMCs and that its release stimulated the migration and proliferation of target cells, with OPN acting both as a matricellular protein and as a soluble factor. Studies in mice revealed that lung OPN expression increased with age, enhanced the proliferative capacity of PA-SMCs in old mice compared with young counterparts, and promoted pulmonary vascular remodeling. OPN −/− mice were not affected by age-dependent pulmonary vascular remodeling and were protected against hypoxia-induced PH. In patients with COPD or iPAH, pulmonary vascular remodeling was associated with marked OPN expression in pulmonary vessels, particularly in association with p16-stained cells. Together with the finding that lung OPN levels correlated with age in controls and in patients with COPD or iPAH, these results support the concept that OPN is a major mediator promoting PH during aging or in age-related lung diseases such as COPD and lung fibrosis.
Whether pulmonary hemodynamic alterations are related to the aging process is an important clinical issue. Pulmonary artery hypertension, whether associated or not associated with an underlying disease, is now common in individuals older than 55 years. 10 Moreover, PH occurs as a complication of various age-related lung diseases such as lung fibrosis and COPD. 11 These facts raise the possibility that specific mechanisms may occur during aging or in association with the cell senescence process to promote pulmonary vascular remodeling and subsequent PH development or progression. Here, we identified OPN as one of the most highly upregulated matricellular proteins in senescent human PA-SMCs. OPN release has been reported previously by fibroblasts and macrophages exposed to inflammatory conditions. 12, 13 Thus, PA-SMCs may release OPN as part of their SASP. OPN is a multifunctional protein that acts as a soluble factor or as a matricellular protein involved in cell-matrix interactions.
14 It is considered a potent mitogenic factor and has been shown to promote paraneoplastic cell growth and to stimulate proliferation of cultured vascular smooth muscle cells. 12, 15, 16 Thus, OPN has been implicated in the pathogenesis of various conditions, including malignancies, autoimmune diseases, and fibrosis. 12, 17, 18 To date, few studies have addressed its role in pulmonary vascular remodeling and PH. In patients with iPAH, circulating OPN levels were elevated and correlated positively with pulmonary arterial hypertension severity and age. 19 Moreover, increased OPN expression has been documented in the lungs of chronically hypoxic calves and monocrotaline-treated rats. 20, 21 We found that senescent cells stimulated the growth and migration of target PA-SMCs through 2 mechanisms, that is, the release of soluble factors and the release of ECM components. In our study, cell proliferation and migration in response to culture media from senescent cells or to matrix deposited by senescent cells were markedly reduced in the presence of neutralizing anti-OPN antibodies. Both autocrine and paracrine effects of OPN on healthy PA-SMCs were demonstrated, and the paracrine effect of OPN was amplified by using media or matrix of senescent PA-SMCs. Senescent cells therefore facilitate the migration and growth of nonsenescent PA-SMCs through stimulation of an OPNrelated process. Interestingly, the ability of the OPN antibody to inhibit migration or proliferation varied according to the experimental conditions. Neutralizing antibodies to OPN were more effective in suppressing PA-SMC migration than proliferation when the cells were studied on a deposited matrix. In contrast, they were more effective in suppressing PA-SMC proliferation than migration when the cells were stimulated by the cell media. These results are consistent with the fact that OPN exists both as an immobilized ECM molecule and as a cytokine in body fluids. OPN contains an integrin-binding RGD sequence and additional sequences that interact with CD44 or other adhesion receptors. The RGD sequence is probably of major importance in PA-SMCs because it completely blocked the growth-promoting effects of exogenous OPN on cultured human PA-SMCs. Moreover, we previously demonstrated that PA-SMCs strongly express CD44, especially in the setting of iPAH. 7 Exogenous osteopontin did not stimulate the growth of senescent cells, although these exhibited increased integrin expression. This finding is consistent with previous evidence that resistance to growth of senescent cells is because of activation of the oncosuppressive proteins p53 and p16. 3 To evaluate whether these findings were relevant to human diseases, we investigated lung samples from patients with COPD and from patients with IPAH. As expected, we found that OPN levels were markedly increased in lung extracts from patients with COPD compared with controls and, interestingly, that lung OPN levels correlated positively with age, in both patients and controls. OPN expression was not restricted to pulmonary vessels but, in those vessels, predominated at sites of vessel wall hypertrophy in association with p16-stained cells. Results obtained in cultured PA-SMCs from patients with COPD and controls confirmed that the increased OPN expression in COPD was chiefly ascribable to the higher proportion of senescent cells. Interestingly, we found a positive correlation between OPN levels and pulmonary arterial wall thickness, indicating a close relationship with the pulmonary vascular remodeling process. These results are therefore consistent with the concept that senescent PA-SMCs contribute to group 3 PH and that OPN is a critical mediator in this process. An intriguing question raised by these results is whether OPN upregulation associated with cell senescence and aging is a mechanism common to various forms of PH. Previous studies of patients with iPAH showed that circulating OPN levels correlated with age. 19 Moreover, circulating OPN correlated negatively with survival in patients with iPAH. 19 Therefore, we investigated lung OPN levels and localization in a small sample of patients with iPAH. We observed a positive correlation between OPN and age, replicating our finding in patients with COPD and controls. OPN staining was markedly increased in remodeled vessels from patients with iPAH, despite their lower p16-stained senescent cell counts compared with patients with COPD. Thus, OPN is upregulated in pulmonary vessels from patients with iPAH, and this OPN overexpression increases further with age.
To further investigate the effects of aging and OPN on PH progression in vivo, we investigated WT mice and OPN −/− mice at various ages. Lung OPN levels increased markedly with age in WT mice, together with the counts of p21-and p16-stained PA-SMCs. Old mice under normoxia had higher right ventricular systolic pressure values and numbers of muscularized vessels compared with young mice. These age-related changes in pulmonary vessels were not seen in OPN −/− mice. Moreover, OPN −/− mice developed less-severe hypoxic PH than relevant control WT mice studied at 2 months or 1 year of age. The oldest WT mice also had increased numbers of p21-and p16-stained PA-SMCs, coexisting with prominent OPN staining in remodeled vessels. These findings therefore support a causal relationship between lung OPN overexpression and the increased PH severity observed in aging mice.
We therefore investigated cultured mouse PA-SMCs. We found that PA-SMCs from old WT mice exhibited an increased proliferative capacity compared with those from younger WT controls. Several arguments strongly support increased OPN synthesis and secretion as the main factor explaining these finding. First, the difference in PA-SMC growth rate between old and young WT mice was abolished in the presence of neutralizing anti-OPN antibodies and was absent when using PA-SMCs from old or young OPN −/− mice. Moreover, medium or matrix from PA-SMCs from old WT mice produced greater stimulation of target cell growth than did medium or matrix from PA-SMCs from young mice. Again, these effects were suppressed by anti-OPN antibodies and were not seen with medium or matrix from old or young OPN −/− mice. Neither medium nor matrix of OPN −/− cells affected the growth of target PA-SMCs. Important conclusions from these observations are that PA-SMC growth is directly affected by aging and that OPN is the main factor responsible for the increased growth capacity of PA-SMCs from aged mice. The role for soluble OPN seemed critical in this process because the growth stimulation induced by PA-SMC media was completely abolished by anti-OPN antibodies. In the present study, we did not investigate the mechanism of osteopontin induction by senescence. Several molecular pathways have been identified as mediating at least part of the SASP: the DNA damage response pathway, the p38MAPK/NF-kB (p38 mitogen-activated protein kinases/ nuclear factor-kappa B) pathway, the mTOR (mammalian target of rapamycin) pathway, and more recently, the JAK1/2-Stat (Janus kinase 1/2-signal transducers and activators of transcription) pathway. 22, 23 Further studies are therefore required to determine which of these pathways is prominently involved in OPN synthesis by senescent pulmonary vascular cells.
That cell senescence favors cell proliferation is now considered as a major hypothesis to explain tumor development. Indeed, senescent fibroblasts have been shown to promote the in vitro and in vivo growth of preneoplastic cells. 12 This observation was taken as evidence that the age-related accumulation of senescent cells in a given tissue collaborates with increasing numbers of preneoplastic cells to increase the incidence of cancer in older individuals. Of note, OPN was shown to be involved in the paracrine stimulation of preneoplastic cell growth. 12 OPN is therefore emerging as a major player in paracrine signaling between senescent cells and nonsenescent cells. In this study, we conclusively demonstrate relationships linking cell senescence, aging, OPN expression, and pulmonary vascular remodeling in experimental animals and in patients with group 1 or group 3 PH. This finding supports the existence of many analogies between cancer and PH, notably group 1 PH. 24 We found that OPN was expressed by aging cells, even those lacking the full complement of senescent cell features, especially in patients with group 1 PH. Thus, OPN may be involved not only in group 3 PH but also in other forms of PH.
Given that pulmonary arterial hypertension is now increasingly diagnosed in elderly patients, our data support a role for specific mechanisms in age-related PH progression and identify OPN as a critical mediator of these mechanisms. OPN may therefore constitute a target for future treatments in various forms of PH, particularly PH in elderly patients.
